Sign in
SuspendedNo phase

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

Key facts

Who runs it
St. Joseph's Hospital and Medical Center, Phoenix
Where
Phoenix and Seattle, United StatesSee the 2 sites
Trial code
Status
Suspended
People taking part
80 people, planned
Started
3 Jun 2020
Ended
Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dural Venous Sinus Stenting
  • Cerebrospinal Fluid Shunting
Record updated
26 September 2024
Why it stopped
Sponsor has suspended the study and is not enrolling any new participants. It is due to funding unavailability.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Diagnosis of Idiopathic Intracranial Hypertension according to the Modified Dandy Criteria
  • Moderate to severe visual field loss defined by perimetric mean deviation of at least -8 dB but better than -30 dB in the worst eye
  • Diagnostic cerebral venography demonstrating a pressure gradient of ≥ 8 mmHg across at least one segment of the dural venous sinus as measured during transfemoral cerebral venography
  • Failure of conservative or non-surgical therapies,by:; failed medical treatment including weight loss regimens OR; medication intolerance OR; medical treatment not indicated per investigator team
  • Women must not be able to become pregnant (e.g., post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study, and have a negative pregnancy test prior to treatment; Women on hormonal birth control must be on a stable dose for at least 3 months prior to enrollment
  • Signed informed consent obtained from the patient

Who cannot take part

  • Previous CSF shunt or diversion procedure of any kind, or previous optic nerve sheath fenestration
  • Previous or ongoing eye disease such as glaucoma or retinopathy
  • Previously (within the last 2 months) or currently exposed to a drug or substance that may elevate intracranial pressure (e.g. lithium, high-dose vitamin A, tetracyclines, anabolic steroids, chlordecone, amiodarone, diphenylhydantoin, nalidixic acid)
  • Uncontrolled second primary headache disorder (e.g. chronic migraine, medication overuse headache)
  • Allergic reaction to radiological iodine contrast agent
  • Presence of a cranial vascular abnormality (arteriovenous malformation, dural arteriovenous fistula, dural venous sinus thrombosis) or other intracranial mass
  • Presence of a hypercoagulable state such as Factor V Leiden, Protein C or S deficiency or anti-cardiolipin syndrome
  • Inability to provide reliable and reproducible visual field examinations (>15% false- positive errors and/or failure to maintain fixation for eye monitoring)
  • Other pre-existing conditions accounting for optic atrophy that could produce irreversible vision loss in the study eye without meeting eligible ophthalmological criteria for IIH in the contralateral eye
  • Condition associated with high risk of retinopathy (e.g. type I diabetes)
  • Presence of a physical, mental or social condition that could prevent adequate follow-up such as terminal illness, homelessness, lack of telephone, drug dependency or anticipation of a significant move away from a study site within one year of enrollment
  • Abnormal CSF analysis such as elevated protein (>60 mg/dL), low glucose (<30 mg/dL), elevated cell count >5 (unless traumatic lumbar puncture)
  • Significant renal impairment (serum creatinine >1.5 mg/dL)
  • CSF pressure <25 cm H2O on lumbar puncture
  • Contraindication to general anesthesia
  • Contraindication to aspirin, clopidogrel or other anticoagulants
  • Pre-existing best corrected visual acuity worse than 20/200 in the study eye as measured by Snellen charts, without meeting eligible ophthalmological criteria in the contralateral eye
  • Pregnancy

Where in United States

  • Barrow Neurological Institute at Dignity Health St. Joseph's Hospital &amp; Medical CenterPhoenix, United States
  • University of Washington Department of NeurosurgerySeattle, United States

About the trial

What the trial wants to find out

Pseudotumor cerebri, also called idiopathic intracranial hypertension (IIH), is characterized by elevated intracranial pressure, headache, and if severe, vision loss. IIH is difficult to treat. Medical management may not adequately resolve the symptoms, and surgical management (primarily through cerebrospinal fluid [CSF] shunting) has a high failure rate. Recently, a relationship between IIH and stenosis of the dural venous sinuses (the veins that drain blood from the brain) has been reported. In patients with IIH in whom there is stenosis of one or more dural venous sinuses, placing a stent in the venous sinus may improve patients' objective symptoms (such as visual loss and papilledema) and subjective symptoms (such as headache). This study will determine whether dural venous sinus stenting is as effective as CSF shunting (considered the standard surgical treatment) in treating IIH patients who have moderate vision loss and stenosis of the dural venous sinuses.

The 2 groups in the trial

  • Dural Venous Sinus StentingTreatment being tested

    Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.

  • Cerebrospinal Fluid ShuntingExisting treatment, for comparison

    Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP)
Record updated
26 September 2024